Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
Parag P. Patwardhan(Columbia University Irving Medical Center), Gary K. Schwartz(Cornell University)
Cited by 112
Related Papers
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
|Journal of Clinical Oncology|2009|573
Aurora Kinases: New Targets for Cancer Therapy
|Clinical Cancer Research|2006|274
Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype
|PLoS ONE|2012|77
90-kDa Heat Shock Protein Inhibition Abrogates the Topoisomerase I Poison-Induced G2/M Checkpoint in p53-Null Tumor Cells by Depleting Chk1 and Wee1
|Molecular Pharmacology|2008|44
MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas
|Oncotarget|2016|34